Heparanase expression: A potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions

Cytopathology

Volumn 18, Issue 1, 2007, Pages 13-19

  Doviner, V ^a   Maly, B ^a   Reinhartz, T ^a   Vlodavsky, I ^b   Sherman, Y ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cytology; Effusions; Heparanase; Immunocytochemistry; Malignant cells; Mesothelial cells; Serons

Indexed keywords

HEPARANASE;

ARTICLE; CANCER CELL; CYTOLOGY; DIAGNOSTIC ACCURACY; EFFUSION; HOSPITAL PATIENT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT MESOTHELIOMA; MESOTHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; EPITHELIUM; EXTRACELLULAR MATRIX; EXUDATES AND TRANSUDATES; GASTROINTESTINAL NEOPLASMS; GLUCURONIDASE; HUMANS; NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33846554800     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2006.00334.x     Document Type: Article

References (46)

1. Kehoe S, Ward K, Luesley D, Chan KK. The application of flow cytophotometric DNA analysis in detecting the presence of malignant cells in ovarian peritoneal fluids. Br J Obstet Gynecol 1995;102:656-9.
2. Chen LM, Lazcano O, Katzman JA, Kimlinger TK, Li CY. The role of conventional cytology, immunocytochemistry, and flow cytometric DNA ploidy in the evaluation of body cavity fluids: a prospective study of 52 patients. Am J Clin Pathol 1998;109:712-21.
3. Osterheld MC, Liette C, Anca M. Image cytometry: an aid for cytological diagnosis of pleural effusions. Diagn Cytopathol 2005;32:173-6.
4. Trevisan MS, Souza MI, Magna LA. Nuclear organizer regions of mesothelial and carcinomatous cells in effusions. Diagn Cytopathol 1993;9:492-7.
5. Huang MS, Tsai MS, Hwang JJ, Wang TH. Comparison of nucleolar organizer regions and DNA flow cytometry in the evaluation of pleural effusion. Thorax 1994;49:1152-6.
6. Zojer N, Angeles J, Mullauer L, Gsur A, Roka S et al. Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patients. Br J Cancer 1977;75:403-7.
7. Athanassiadou PP, Veneti SZ, Kyrkou KA, Atthanassiades PH. Detection of c-Ha-ras oncogene expression in pleural and peritoneal smear effusions by in situ hybridization. Cancer Detect Prevent 1993;17:585-90.
8. Yamashita K, Kuba T, Shinoda H, Takahashi E, Okayasu I. Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. Am J Clin Pathol 1998;109:704-11.
9. Yamamoto Y, Hirakawa E. Telomerase activity and hTERT mRNA expression in body fluids. Diagn Pathol 2005;32:167-70.
10. Nieh S, Chen SF, Fu E, Jan CI, Lee WH. Detection of human telomerase RNA component by in situ hybridization in cells from body fluids. Acta Cytol 2005;49:31-7.
11. Politi E, Kandaraki C, Apostolopoulu C, Kyristi T, Koustelini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151-5.
12. Singh HK, Silverman JF, Berns L, Haddad MG, Park HK. Significance of epithelial membrane antigen in the workup of problematic serous effusions. Diagn Cytopathol 1995;13:3-7.
13. Esteban JM, Yokota S, Husain S, Battifora H. Immunocytochemical profile of benign and carcinomatous effusions. A practical approach to difficult diagnosis. Am J Pathol 1990;94:698-705.
14. Wolanski KD, Whitaker D, Shilkin KB, Henderson DW. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer Cytopathol 1998;82:583-90.
15. Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A et al. The role of Desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-12.
16. Pereira T, Saad RS, Liu LY, Silverman JF. E-cadherin is a useful immunohistochemical (IHC) marker for differentiating benign from malignant proliferations. Mod Pathol 2003;16:312A (abstr.).
17. Dejmek A, Hjerpe A. The combination of CEA, EMA, and Berp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 2005;32:160-6.
18. Itzkowitz SH, Bloom Ej, Kokal WA, Modin G, Hakomori S et al. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990;66:1960-6.
19. Bresalier RS, Ho SB, Schoeppner HL, Kim YS, Sleisenger MH et al. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology 1996;110:1354-67.
20. Zimmerman RL, Fogt F, Bibbo M. Diagnostic utility of Sialosyl-Tn in discriminating carcinomatous cells from benign mesothelium in body cavity effusions. Acta Cytol 1999;43:1079-84.
21. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-73.
22. Duffy MJ, The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145-55.
23. Nakajima M, Irimura T, Nicolson GL. Heparanase and tumor metastasis. J Cell Biochem 1988;36:157-67.
24. Vlodavsky I, Moshen M, Lider O, Svahn CM, Ekre HP et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 1995;14:290-302.
25. Jackson RL, Busch SJ, Cardin AL. Glycosaminoglycans: molecular properties, protein interactions and role in physiological processes. Physiol Rev 1991;71:481-539.
26. Wight TN, Kinsella MG, Qwamstromn EE. The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 1992;4:793-801.
27. Rapraeger AC, The coordinated regulation of heparan sulfate, syndecans and cell behavior. Curr Opin Cell Biol 1993;5:844-53.
28. Vlodavsky I, Miao HQ, Benezra M, Lider O, Bar-Shavit R et al. Involvement of the extracellular matrix, heparan sulfate proteoglycans and heparan sulfate degrading enzymes in angiogenesis and metastasis. In: Tumor Angiogenesis. Lewis CE, Bicknell R, Ferrara N (eds). Oxford: Oxford University Press; 1997: pp. 125-40.
29. Ohkawa T, Naomoto Y, Takaoka M, Nobuhisa T, Noma K et al. Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest 2004;84:1289-304.
30. Tang W, Nakamura Y, Tsujimoto M, Sato M, Wang X et al. Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 2002;15:593-8.
31. Kuniyasu H, Chihara Y, Kubozoe T, Takahashi T. Co-expression of CD44v3 and heparanase is correlated with metastasis of human colon cancer. Int J Mol Med 2002;10:333-7.
32. Rohloff J, Zinke J, Schoppmeyer K, Tannapfel A, Witzigmann H et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer 2002;86:1270-5.
33. Liu Y, Xin XY, Han LF, Wang DT. The expression of acetyl-heparanase, laminin and laminin receptor and their role in the metastasis of ovarian cancer. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2003;19:459-61.
34. Takahashi H, Ebihara S, Okazaki T, Suzuki S, Asada M et al. Clinical significance of heparanase activity in primary resected non-small cell lung cancer. Lung Cancer 2004;45:207-14.
35. Chen JQ, Zhan WH, He YL, Peng JS, Wang JP et al. Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol 2004;10:776-82.
36. Ginath S, Menczer J, Friedmann Y, Aingorn H, Aviv A et al. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer. Int J Oncol 2001;18:1133-44.
37. Frost JK. The cell in health and disease - an evaluation of cellular morphologic expression of biologic behavior. In: Monographs in Clinical Cytology. Wied GI (ed.). New York: Karger; 1986: pp. 12-28.
38. Ordóñez NG, Mackay B. The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma. Adv Anat Pathol 1996;3:273-93.
39. Oates J, Edwards C. HMBE-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-7.
40. Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid Schiff, monoclonal antibodies B72.3 and Leu-M1. Am J Pathol 1988;133:30-38.
41. Brown RW, Clark GM, Tandom AK, Allred DC. Multiple marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1997;10:716-9.
42. Bailey ME, Brown RW, Mody DR, Cagle P, Ramzy I. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous fluids: comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Acta Cytol 1996;40:1212-6.
43. García-Prats MD, Ballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JI. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumors. Histopathology 1998;32:462-72.
44. Ordóñez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma: the M. D. Anderson experience and a critical review of the literature. Am J Clin Pathol 1998;109:85-9.
45. Ordóñez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-14.
46. González-Lois C, Ballestin C, Sotelo MT, López-Ríos F, García-Prats MD et al. Combined use of novel epithelial (MOC-31) and mesothelial (HMBE-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001;38:528-34.